Generic Medicine Info
May be taken with or without food.
Acute narrow-angle glaucoma, severe respiratory insufficiency, severe respiratory failure, acute respiratory depression, myasthenia gravis, sleep apnoea syndrome; severe hepatic impairment (oral). Concomitant use with CYP3A4 inhibitors.
Special Precautions
Patient with uncompensated acute illnesses (e.g. severe fluid or electrolyte disturbances), CV disease (e.g. heart failure), respiratory disease (e.g. COPD), history of alcohol or drug abuse; at risk of falls; obese, debilitated. Avoid abrupt withdrawal. Renal and hepatic impairment. Elderly and children. Pregnancy and lactation. Patient Counselling This drug may cause sedation, amnesia, impaired concentration and muscular function, if affected, do not drive or operate machinery. Monitoring Parameters Monitor the level of sedation, respiratory rate, heart rate, blood pressure, oxygen saturation (e.g. pulse oximetry), vital signs.
Adverse Reactions
Significant: Anterograde amnesia, CNS depression, hypotension, paradoxical reactions (e.g. hyperactive or aggressive behaviour), suicidal ideation, withdrawal symptoms. Cardiac disorders: Bradycardia, tachycardia. Gastrointestinal disorders: Nausea, vomiting, constipation, dry mouth, hiccups. General disorders and administration site conditions: Fatigue, inj site reactions (e.g. erythema, pain, phlebitis, thrombosis). Injury, poisoning and procedural complications: Falls, fractures. Musculoskeletal and connective tissue disorders: Muscle weakness. Nervous system disorders: Sedation (prolonged and post-operative), decreased alertness, somnolence, headache, dizziness, drowsiness, ataxia. Psychiatric disorders: Confusion, euphoric mood, depression, hallucinations, physical drug dependence, withdrawal syndrome. Respiratory, thoracic and mediastinal disorders: Dyspnoea, laryngospasm, bronchospasm, cough. Skin and subcutaneous tissue disorders: Rash, urticaria, pruritus.
Potentially Fatal: Cardiorespiratory effects (e.g. respiratory depression, respiratory arrest, apnoea, cardiac arrest).
Drug Interactions
Decreased plasma concentration with CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenytoin). Potentiate the action of antipsychotics, barbiturates, propofol, ketamine, sedative antidepressants, antihistamines and centrally acting antihypertensive drugs.
CIMS Class
Hypnotics & Sedatives
ATC Classification
N05CD08 - midazolam ; Belongs to the class of benzodiazepine derivatives. Used as hypnotics and sedatives.
Disclaimer: This information is independently developed by CIMS based on midazolam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in